DECLARE TIMI 58 Trial Summary: Wiviott et al. randomized 17,160 patients with DMII (HbA1c 6.5-12%) who had multiple risk factors for or had established atherosclerotic CV disease to either dapagliflozin or a placebo. Their objective was to assess the cardiovascular safety profile of dapagliflozin, a selective inhibitor of SGLT2 in patients with type 2 diabetes…
2017, CANTOS Trial: Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease, NEJM The CANTOS trial evaluated the inflammatory nature of coronary artery disease where hypothesis was that decreasing the inflammation marker such as interleukin 1B will result in lower incidence of cardiovascular events. For this purpose, canakinumab which is a monoclonal antibody against IL-1B was tested..
FOURIER Trial Key Points: FOURIER trial established the role of PCSK9 inihibitor therapy in reducing future cardiovascular events and mortality. Evolocumab showed benefit in terms of cardiovascular disease but didn’t show any mortality benefit. These agents were utilized in patients who were already on moderate to high intensity statin therapy. PCSK9 inhibition was well-tolerated without excess new-onset diabetes..
2016, Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease, NEJM EXCEL Trial Summary Summarized by Lina Ya’qoub, MD – Cardiovascular disease fellow at Louisiana State University Methods The Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial is an international, open-label, non-inferiority, multicenter randomized trial that..
1998, Pravastatin in patients with coronary heart disease, NEJM
2008, Extended-release metoprolol succinate in patients undergoing non-cardiac surgery, The Lancet